FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016623905> ?p ?o ?g. }

• W2016623905 endingPage "1892" @default.
• W2016623905 startingPage "1882" @default.
• W2016623905 abstract "Background. Chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS) is a condition involving thrombocytopenia, microangiopathic hemolytic anemia, and progressive renal dysfunction that develops in 2–10% of patients with a history of malignant neoplasms treated with certain chemotherapeutic agents. Pathogenesis of the disease may depend on the following: (1) generation of endothelial lesions in the kidney microvasculature, resulting from drug toxic effects and/or generation of small soluble circulating immune complexes (CIC), and (2) generation of autoantibodies and/or CIC that trigger aggregation and deposition of platelets around the lesions. Methods. Extracorporeal immunoadsorption treatment of plasma (PROSORBA columns, IMRÉ Corporation, Seattle, WA) to remove immunoglobulin G and CIC was evaluated in 55 patients for the potential to induce significant clinical benefits (increase in platelet count, decrease in hemolysis, stabilization of renal function) and longer survival. Results. Response to therapy was achieved in 25 of 55 patients examined. Response was associated with an estimated 1-year survival rate of 61%, as compared with an estimated survival rate of only 22% in those who did not respond (P = 0.0001). Patients whose malignant neoplasms were in complete or partial remission at the time of development of C-TTP/HUS had a significantly higher estimated 1-year survival rate (74%) as compared with a historic control group of patients receiving other treatments (22%, P = 0.0161). Clinical responses were correlated with normalization of serum levels of CIC and complement components C3c and C4. There were no side effects associated with 75% of treatments. Immunoadsorption therapy was associated with generally mild to moderate manageable side effects, such as fever, chills, nausea/vomiting, respiratory symptoms, pain, hypertension, and hypotension, which were reported in 25% of procedures. Conclusions. This multicenter study establishes protein A immunoadsorption as an effective and safe treatment for cancer chemotherapy-associated TTP/HUS, an otherwise fatal disease." @default.
• W2016623905 created "2016-06-24" @default.
• W2016623905 creator A5010849593 @default.
• W2016623905 creator A5012507181 @default.
• W2016623905 creator A5023199742 @default.
• W2016623905 creator A5023288235 @default.
• W2016623905 creator A5031957382 @default.
• W2016623905 creator A5045214490 @default.
• W2016623905 creator A5045953251 @default.
• W2016623905 creator A5051108217 @default.
• W2016623905 creator A5052081284 @default.
• W2016623905 creator A5055257479 @default.
• W2016623905 creator A5057261493 @default.
• W2016623905 creator A5059305071 @default.
• W2016623905 creator A5065856664 @default.
• W2016623905 creator A5069835475 @default.
• W2016623905 creator A5085244083 @default.
• W2016623905 date "1993-03-01" @default.
• W2016623905 modified "2023-10-18" @default.
• W2016623905 title "Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma" @default.
• W2016623905 cites W1843793148 @default.
• W2016623905 cites W1917101340 @default.
• W2016623905 cites W1966217731 @default.
• W2016623905 cites W1970635209 @default.
• W2016623905 cites W1989227565 @default.
• W2016623905 cites W1990031841 @default.
• W2016623905 cites W1991079138 @default.
• W2016623905 cites W1999210336 @default.
• W2016623905 cites W2010978111 @default.
• W2016623905 cites W2021606923 @default.
• W2016623905 cites W2023931095 @default.
• W2016623905 cites W2032337745 @default.
• W2016623905 cites W2039573203 @default.
• W2016623905 cites W2052015578 @default.
• W2016623905 cites W2053526294 @default.
• W2016623905 cites W2075788990 @default.
• W2016623905 cites W2076807191 @default.
• W2016623905 cites W2078142403 @default.
• W2016623905 cites W2087317416 @default.
• W2016623905 cites W2089488243 @default.
• W2016623905 cites W2094083449 @default.
• W2016623905 cites W2095433984 @default.
• W2016623905 cites W2100888057 @default.
• W2016623905 cites W2137640093 @default.
• W2016623905 cites W2140859241 @default.
• W2016623905 cites W2141076873 @default.
• W2016623905 cites W2234763517 @default.
• W2016623905 cites W2256370784 @default.
• W2016623905 cites W4232737302 @default.
• W2016623905 cites W4237488345 @default.
• W2016623905 cites W4298367589 @default.
• W2016623905 doi "https://doi.org/10.1002/1097-0142(19930301)71:5<1882::aid-cncr2820710527>3.0.co;2-e" @default.
• W2016623905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8448753" @default.
• W2016623905 hasPublicationYear "1993" @default.
• W2016623905 type Work @default.
• W2016623905 sameAs 2016623905 @default.
• W2016623905 citedByCount "101" @default.
• W2016623905 countsByYear W20166239052013 @default.
• W2016623905 countsByYear W20166239052014 @default.
• W2016623905 countsByYear W20166239052015 @default.
• W2016623905 countsByYear W20166239052016 @default.
• W2016623905 countsByYear W20166239052018 @default.
• W2016623905 countsByYear W20166239052019 @default.
• W2016623905 countsByYear W20166239052020 @default.
• W2016623905 countsByYear W20166239052021 @default.
• W2016623905 countsByYear W20166239052022 @default.
• W2016623905 countsByYear W20166239052023 @default.
• W2016623905 crossrefType "journal-article" @default.
• W2016623905 hasAuthorship W2016623905A5010849593 @default.
• W2016623905 hasAuthorship W2016623905A5012507181 @default.
• W2016623905 hasAuthorship W2016623905A5023199742 @default.
• W2016623905 hasAuthorship W2016623905A5023288235 @default.
• W2016623905 hasAuthorship W2016623905A5031957382 @default.
• W2016623905 hasAuthorship W2016623905A5045214490 @default.
• W2016623905 hasAuthorship W2016623905A5045953251 @default.
• W2016623905 hasAuthorship W2016623905A5051108217 @default.
• W2016623905 hasAuthorship W2016623905A5052081284 @default.
• W2016623905 hasAuthorship W2016623905A5055257479 @default.
• W2016623905 hasAuthorship W2016623905A5057261493 @default.
• W2016623905 hasAuthorship W2016623905A5059305071 @default.
• W2016623905 hasAuthorship W2016623905A5065856664 @default.
• W2016623905 hasAuthorship W2016623905A5069835475 @default.
• W2016623905 hasAuthorship W2016623905A5085244083 @default.
• W2016623905 hasBestOaLocation W20166239051 @default.
• W2016623905 hasConcept C121608353 @default.
• W2016623905 hasConcept C126322002 @default.
• W2016623905 hasConcept C159641895 @default.
• W2016623905 hasConcept C159654299 @default.
• W2016623905 hasConcept C163764329 @default.
• W2016623905 hasConcept C203014093 @default.
• W2016623905 hasConcept C2776175824 @default.
• W2016623905 hasConcept C2776283816 @default.
• W2016623905 hasConcept C2776694085 @default.
• W2016623905 hasConcept C2777878052 @default.
• W2016623905 hasConcept C2778585876 @default.
• W2016623905 hasConcept C2778842783 @default.
• W2016623905 hasConcept C2779134260 @default.
• W2016623905 hasConcept C2779839709 @default.

• next